%0 Journal Article
%A Spittel, Susanne
%A Grehl, Torsten
%A Weydt, Patrick
%A Kettemann, Dagmar
%A Fabian, Rachel
%A Rödiger, Annekathrin
%A Smesny, Uta
%A Steinbach, Robert
%A Ilse, Benjamin
%A Weyen, Ute
%A Petri, Susanne
%A Lumi, Rea
%A Bjelica, Bogdan
%A Lingor, Paul
%A Grosskreutz, Julian
%A Göricke, Bettina M
%A Pfeilschifter, Waltraud
%A Schmeja, Wibke
%A Dorst, Johannes
%A Mensch, Alexander
%A Siebert, Jürgen
%A Norden, Jenny
%A Bernsen, Sarah
%A Subramanian, Senthil Kumar
%A Hildebrandt, Barbara
%A Walter, Bertram
%A Münch, Christoph
%A Maier, André
%A Meyer, Thomas
%T Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter study.
%J Amyotrophic lateral sclerosis & frontotemporal degeneration
%V 27
%N 1-2
%@ 2167-8421
%C Abingdon
%I Taylor Francis Group
%M DZNE-2026-00157
%P 185 - 197
%D 2026
%X In amyotrophic lateral sclerosis (ALS), dextromethorphan/quinidine (DMQ) has been reported to reduce bulbar symptoms, including dysarthria and dysphagia. However, data on patients' perceptions of DMQ treatment are limited.Data on DMQ treatment were collected from 1065 ALS patients treated at 13 ALS centers between 10-2015 and 06-2025. Patient-reported outcome measures (PROM) of 179 participants were remotely assessed via the 'ALS App'. PROM included the self-explanatory version of the ALS Functional Rating Scale (ALSFRS-R-SE), the Net Promoter Score (NPS); and Treatment Satisfaction Questionnaire for Medication (TSQM-9).Mean disease duration was 29.3 months (SD 38.1). ALS progression before treatment was 0.82 points/month (ALSFRS-R). Mean DMQ treatment duration was 8.4 months (SD 10.8), including 35.2
%K Humans
%K Dextromethorphan: therapeutic use
%K Amyotrophic Lateral Sclerosis: drug therapy
%K Amyotrophic Lateral Sclerosis: complications
%K Male
%K Female
%K Middle Aged
%K Quinidine: therapeutic use
%K Aged
%K Patient Reported Outcome Measures
%K Drug Combinations
%K Treatment Outcome
%K Patient Satisfaction
%K Adult
%K Amyotrophic lateral sclerosis (Other)
%K bulbar symptoms (Other)
%K dextromethorphan/quinidine (DMQ) (Other)
%K dysarthria (Other)
%K dysphagia (Other)
%K patient-reported outcomes (Other)
%K Dextromethorphan (NLM Chemicals)
%K Quinidine (NLM Chemicals)
%K dextromethorphan - quinidine combination (NLM Chemicals)
%K Drug Combinations (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40932199
%R 10.1080/21678421.2025.2557932
%U https://pub.dzne.de/record/285032